Asthma and chronic obstructive pulmonary disease (Asthma/COPD) are a common type of chronic disease. Once they are sick, they usually need long-term medication, which seriously affects people's quality of life.
The 2016 Global Asthma Prevention Initiative (GINA) organization has re-released its Consensus on Asthma, COPD and Asthma-COPD Overlap Syndrome, developed in collaboration with the Global Scientific Committee on Chronic Obstructive Pulmonary Disease Prevention (GOLD). A method of identifying such patients is provided.

The global Asthma and COPD Drug market was valued at 5200 million US$ in 2018 and will reach 8040 million US$ by the end of 2025, growing at a CAGR of 5.6% during 2019-2025.
This report focuses on Asthma and COPD Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Asthma and COPD Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Asthma and COPD Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Asthma and COPD Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Boehringer Ingelheim
GlaxoSmithKline
Merck and Co
Novartis AG
AstraZeneca
F. Hoffmann-La Roche
...

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Bronchodilators
Anti-inflammatory Drugs
Monoclonal Antibodies
Combination Drugs

Segment by Application
Asthma
COPD